The story of copyright's flagship drug presents a interesting case for stakeholders in the drug sector. While initially a phenomenal success, creating huge profits, the intellectual property lapse and the subsequent entry of generic alternatives have drastically impacted earnings. This presents questions about the future sustainability of similar d